Akademska digitalna zbirka SLovenije - logo

Search results

Basic search    Expert search   

Currently you are NOT authorised to access e-resources SI consortium. For full access, REGISTER.

1
hits: 7
1.
  • Obinutuzumab plus bendamust... Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
    Sehn, Laurie H, Dr; Chua, Neil, MD; Mayer, Jiri, Prof ... The lancet oncology, 08/2016, Volume: 17, Issue: 8
    Journal Article
    Peer reviewed

    Summary Background Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate disease control with rituximab-based treatment have few treatment options and a poor prognosis. We aimed to ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK, ZRSKP
2.
  • Lenalidomide versus investi... Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
    Trněný, Marek, Prof; Lamy, Thierry, Prof; Walewski, Jan, Prof ... The lancet oncology, 03/2016, Volume: 17, Issue: 3
    Journal Article
    Peer reviewed

    Summary Background Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed activity in many single-group studies in relapsed or refractory mantle cell ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
3.
  • Nivolumab for classical Hod... Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
    Younes, Anas, Prof; Santoro, Armando, Prof; Shipp, Margaret, Prof ... The lancet oncology, 09/2016, Volume: 17, Issue: 9
    Journal Article
    Peer reviewed
    Open access

    Summary Background Malignant cells of classical Hodgkin's lymphoma are characterised by genetic alterations at the 9p24.1 locus, leading to overexpression of PD-1 ligands and evasion of immune ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK

PDF
4.
  • First-line chemoimmunothera... First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
    Eichhorst, Barbara, Dr; Fink, Anna-Maria, MD; Bahlo, Jasmin, PhD ... The lancet oncology, 07/2016, Volume: 17, Issue: 7
    Journal Article
    Peer reviewed

    Summary Background Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is the standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia. This ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
5.
  • CHOP-like chemotherapy with... CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
    Pfreundschuh, Michael, Prof; Kuhnt, Evelyn, MSc; Trümper, Lorenz, Prof ... The lancet oncology, 10/2011, Volume: 12, Issue: 11
    Journal Article
    Peer reviewed

    Summary Background The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
6.
  • Ibrutinib versus temsirolim... Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
    Dreyling, Martin, Prof Dr; Jurczak, Wojciech, MD; Jerkeman, Mats, MD ... The Lancet (British edition), 02/2016, Volume: 387, Issue: 10020
    Journal Article
    Peer reviewed
    Open access

    Summary Background Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis. Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed or ...
Full text
Available for: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK, ZRSKP

PDF
7.
  • Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial
    Assouline, Sarit; Buccheri, Valeria; Delmer, Alain ... The Lancet. Haematology, 03/2016, Volume: 3, Issue: 3
    Journal Article
    Peer reviewed

    Part one of the two-part SAWYER study predicted that subcutaneous rituximab 1600 mg would achieve trough serum concentrations that were non-inferior to those achieved with intravenous rituximab 500 ...
Full text
Available for: OILJ
1
hits: 7

Load filters